Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: pwrmstr who wrote (75)	2/12/1998 8:55:00 PM
From: Darth Vader	Read Replies (1) \| Respond to of 184

Any feedback from you Roche contacts? Based on my info Sturges' posts are totally out of line...following today's Letter of Deficiency by the FDA Sang 35 should be on the market by mid year and SANG could break-even by year-end. I am still looking at SANG 35 capturing 10% of the Cyclo market by late next year, i.e. revenues for the company in excess of $300m...I will let you calculate the margins!!! P.S. I hear Novartis really tried to stop the FDA but failed!